18206-06-9

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dimethylpyridine-4-carboxaldehyde is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to form complex molecular structures that can exhibit therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-Dimethylpyridine-4-carboxaldehyde is employed as a building block for the development of new agrochemicals, potentially enhancing crop protection and yield.
Used in Polymer Production:
2,6-Dimethylpyridine-4-carboxaldehyde is used as a reagent in the production of high-performance polymers, contributing to the creation of materials with improved mechanical, thermal, and chemical properties.
Used in Fragrance Industry:
In cosmetics and personal care products, 2,6-Dimethylpyridine-4-carboxaldehyde is used as a fragrance ingredient, leveraging its strong odor to create distinctive scents for various applications.

InChI:InChI=1/C8H9NO/c1-6-3-8(5-10)4-7(2)9-6/h3-5H,1-2H3

Upstream product

• 108-75-8 2,4,6-trimethyl-pyridine 
• 67-68-5 dimethyl sulfoxide 
• 108-48-5 2,6-dimethylpyridine 
• 18088-01-2 2,6-dimethyl-4-pyridinemethanol 
• 1073-23-0 2,6-lutidine N-oxide 

Downstream Products

• 54221-93-1 2,6-dimethylisonicotinic acid 
• 142896-15-9 methyl 2,6-dimethylpyridine-4-carboxylate 
• 1246251-24-0 2-(2,6-dimethylpyridin-4-yl)-7-fluoro-5-(2-phenoxyethoxy)-3H-quinazolin-4-one 
• 1246251-23-9 2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-phenoxyethoxy)quinazolin-4(3H)-one 
• 1246251-30-8 7-(2-(benzyloxy)ethoxy)-2-(2,6-dimethylpyridin-4-yl)-5-methoxyquinazolin-4(3H)-one 
• 1246251-22-8 2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-phenoxyethoxy)quinazolin-4(3H)-one 

Relevant academic research and scientific papers

Anti-inflammatory agents

Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

Selective photosensitization through an and logic response: Optimization of the pH and glutathione response of activatable photosensitizers

A series of pH and GSH responsive photosensitizers were designed and synthesized. pKa values were optimized by adjusting the inductive contribution of substituents to reach a pH range (6.0-7.4) relevant to the tumour microenvironment. pH-Activatable behaviour and redox mediated release of the quencher from the PS by GSH allow the construction of an AND logic operator for selective photodynamic action in aqueous solutions.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

REACTIVITY OF METHYL DERIVATIVES OF NITROGENOUS HETEROCYCLES IN VAPOR-PHASE CATALYTIC OXIDATION

A study has been made of the reactivity of methylpyridines, methylpyrazines, and methylquinolines in oxidation in the vapor phase in the presence of β-VO(PO3)2.Relationships have been found between the overall reaction rates of heterocyclic compounds and the charge on the ring nitrogen, and between the partial oxidation rate and the charge on the ring carbon atom adjacent to the methyl group.The partial oxidation rate of methylpyridines is given to a first approximation by the Hammett-type expression lnWa = -3.5 + 4.6 Σ?, with a correlation coefficient of 0.93.